Celcuity (CELC) Stock Forecast, Price Target & Predictions
CELC Stock Forecast
Celcuity stock forecast is as follows: an average price target of $31.50 (represents a 110.28% upside from CELC’s last price of $14.98) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
CELC Price Target
The average price target for Celcuity (CELC) is $31.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $39.00 to $24.00. This represents a potential 110.28% upside from CELC's last price of $14.98.
CELC Analyst Ratings
According to 5 Wall Street analysts, Celcuity's rating consensus is 'Buy'. The analyst rating breakdown for CELC stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Celcuity Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 15, 2024 | Bradley Canino | Stifel Nicolaus | $39.00 | $16.57 | 135.37% | 160.35% |
| May 30, 2024 | Bradley Canino | Stifel Nicolaus | $40.00 | $15.28 | 161.78% | 167.02% |
| Mar 28, 2024 | Gil Blum | Needham | $24.00 | $18.16 | 32.16% | 60.21% |
The latest Celcuity stock forecast, released on Aug 15, 2024 by Bradley Canino from Stifel Nicolaus, set a price target of $39.00, which represents a 135.37% increase from the stock price at the time of the forecast ($16.57), and a 160.35% increase from CELC last price ($14.98).
Celcuity Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $39.00 | $34.33 |
| Last Closing Price | $14.98 | $14.98 | $14.98 |
| Upside/Downside | -100.00% | 160.35% | 129.17% |
In the current month, the average price target of Celcuity stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Celcuity's last price of $14.98. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 15, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jul 22, 2024 | Jefferies | Buy | Buy | Hold |
| Mar 28, 2024 | Craig-Hallum | Buy | Buy | Hold |
| Mar 28, 2024 | Needham | Buy | Buy | Hold |
| Oct 11, 2021 | Canaccord Genuity | - | Buy | Initialise |
Celcuity's last stock rating was published by Cowen & Co. on Aug 15, 2024. The company gave CELC a "Buy" rating, the same as its previous rate.
Celcuity Financial Forecast
Celcuity Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $28.60M | $14.30M | $92.80M | $92.80M | $1.27M | $550.00K | - | - | $4.41M | $1.89M | - | - | - |
| High Forecast | $28.60M | $14.30M | $92.80M | $92.80M | $1.27M | $550.00K | - | - | $4.41M | $1.89M | - | - | - |
| Low Forecast | $28.60M | $14.30M | $92.80M | $92.80M | $1.27M | $550.00K | - | - | $4.41M | $1.89M | - | - | - |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
Celcuity's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CELC's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Celcuity EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-19.70M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict CELC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Celcuity's previous annual EBITDA (undefined) of $NaN.
Celcuity Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-18.85M |
| Avg Forecast | $-21.14M | $-28.45M | $-34.22M | $-30.37M | $-32.99M | $-31.29M | $-30.06M | $-28.14M | $-27.13M | $-25.10M | $-26.09M | $-23.39M | $-21.05M |
| High Forecast | $-21.14M | $-28.45M | $-34.22M | $-30.37M | $-32.99M | $-31.29M | $-30.06M | $-28.14M | $-27.13M | $-21.24M | $-26.09M | $-23.39M | $-15.12M |
| Low Forecast | $-21.14M | $-28.45M | $-34.22M | $-30.37M | $-32.99M | $-31.29M | $-30.06M | $-28.14M | $-27.13M | $-27.80M | $-26.09M | $-23.39M | $-27.57M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.90% |
Celcuity's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CELC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Celcuity SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $1.62M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
Celcuity's average Quarter SG&A projection for Mar 24 is -, based on 2 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to CELC last annual SG&A of $1.62M (Dec 23).
Celcuity EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.65 |
| Avg Forecast | $-0.55 | $-0.74 | $-0.89 | $-0.79 | $-0.86 | $-0.81 | $-0.78 | $-0.73 | $-0.71 | $-0.65 | $-0.68 | $-0.70 | $-0.73 |
| High Forecast | $-0.55 | $-0.74 | $-0.89 | $-0.79 | $-0.86 | $-0.81 | $-0.78 | $-0.73 | $-0.71 | $-0.55 | $-0.68 | $-0.70 | $-0.52 |
| Low Forecast | $-0.55 | $-0.74 | $-0.89 | $-0.79 | $-0.86 | $-0.81 | $-0.78 | $-0.73 | $-0.71 | $-0.72 | $-0.68 | $-0.70 | $-0.95 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.89% |
According to undefined Wall Street analysts, Celcuity's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CELC previous annual EPS of $NaN (undefined).
Celcuity Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
| HOWL | Werewolf Therapeutics | $2.34 | $12.00 | 412.82% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| RZLT | Rezolute | $5.25 | $13.00 | 147.62% | Buy |
| ACRV | Acrivon Therapeutics | $8.91 | $21.50 | 141.30% | Buy |
| CELC | Celcuity | $14.98 | $31.50 | 110.28% | Buy |
| CCCC | C4 Therapeutics | $6.44 | $11.33 | 75.93% | Hold |
| ADAG | Adagene | $3.49 | $5.00 | 43.27% | Buy |
| ANAB | AnaptysBio | $40.33 | $36.33 | -9.92% | Buy |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
CELC Forecast FAQ
Is Celcuity a good buy?
Yes, according to 5 Wall Street analysts, Celcuity (CELC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of CELC's total ratings.
What is CELC's price target?
Celcuity (CELC) average price target is $31.5 with a range of $24 to $39, implying a 110.28% from its last price of $14.98. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Celcuity stock go up soon?
According to Wall Street analysts' prediction for CELC stock, the company can go up by 110.28% (from the last price of $14.98 to the average price target of $31.5), up by 160.35% based on the highest stock price target, and up by 60.21% based on the lowest stock price target.
Can Celcuity stock reach $20?
CELC's average twelve months analyst stock price target of $31.5 supports the claim that Celcuity can reach $20 in the near future.
What are Celcuity's analysts' financial forecasts?
Celcuity's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.82M (high $1.82M, low $1.82M), average EBITDA is $0 (high $0, low $0), average net income is $-122M (high $-122M, low $-122M), average SG&A $0 (high $0, low $0), and average EPS is $-3.186 (high $-3.186, low $-3.186). CELC's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $228.5M (high $228.5M, low $228.5M), average EBITDA is $0 (high $0, low $0), average net income is $-114M (high $-114M, low $-114M), average SG&A $0 (high $0, low $0), and average EPS is $-2.97 (high $-2.97, low $-2.97).